EichorEICHOR
Study identifier: NCT07639021 Synced from ClinicalTrials.gov · August 08, 2026
● Study status: Recruiting

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

Condition: Obesity  ·  Sponsor: Novo Nordisk A/S

PhasePhase 2
Planned participants230
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNoCheck eligibility criteria ↓
Where25 locations · 2 countries

Interested? Contact the study team ↓

Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.

About this study

The purpose of the study is to find out if NNC0662-0419 is safe and effective for treating participants living with obesity.

This description comes directly from the study's public registry record.

Talk to the study team

Novo Nordisk  ·  (+1) 866-867-7178  ·  clinicaltrials@novonordisk.com

There is no obligation to join — the study team can answer your questions about taking part.

Always discuss trial participation with your own doctor first.

Full eligibility criteria (exactly as the study team wrote them)

Inclusion Criteria: * Male or female (sex assigned at birth, inclusive of all gender identities). * Age 18 years or above at the time of signing the informed consent. * Body mass index (BMI) greater than or equal to (≥) 30.0 kilogram per square meter (kg/m\^2) at screening. * Participant must have a desire and be committed to lose at least 25 percentage (%) of their body weight from randomisation. Exclusion Criteria: * Known or suspected hypersensitivity to study intervention(s) or related products. * Treatment with any medication prescribed for the indication of obesity or weight management (e.g. glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues)) within 90 days before screening. * Glycated haemoglobin (HbA1c) ≥ 6.5% (48 Millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening. * History of type 1 or type 2 diabetes mellitus.

Reproduced word-for-word from the public registry record — the study team can answer questions about it.

Locations (25)

Chambliss Clinical Trials, LLCMontgomery, Alabama, United StatesRecruiting
FDRCCosta Mesa, California, United StatesRecruiting
Los Angeles Institute for Metabolic ResearchLos Angeles, California, United StatesRecruiting
Encore Medical Research LLCHollywood, Florida, United StatesRecruiting
South Broward Research LLCMiramar, Florida, United StatesRecruiting
West Orange EndocrinologyOcoee, Florida, United StatesRecruiting
Cedar-Crosse Research CenterChicago, Illinois, United StatesRecruiting
Great Lakes Clinical TrialsChicago, Illinois, United StatesRecruiting
Midwest Inst For Clin ResIndianapolis, Indiana, United StatesNot Yet Recruiting
L-MARC Research CenterLouisville, Kentucky, United StatesRecruiting
Endo And Metab ConsRockville, Maryland, United StatesRecruiting
StudyMetrix Research LLCCity of Saint Peters, Missouri, United StatesRecruiting

+ 13 more locations — full list on the registry record.

More studies in these areas

This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.

MontgomeryCosta MesaLos AngelesHollywood

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.

Look up another condition
Look up another city
Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →